CSL surged about 16% to roughly A$156.7 on Tuesday, a one-day jump of ~A$22 from Monday's A$134.60 close — one of the biggest single-session moves in the ASX 200. The twist: it landed on the same morning CSL booked a US$2.6 billion statutory loss.

So why does a company that just posted a multibillion-dollar loss rip higher? Because almost none of that loss was cash. The red ink came from ~US$7.1 billion of impairments and restructuring charges (including US$799m of restructuring), tied to a weaker commercial outlook, generic competition and changed site-utilisation assumptions. Strip the one-offs out and the underlying business still made money: revenue of US$15.8b (down ~1%) and underlying NPATA of US$3.1b (down ~2%), with management branding FY26 a "reset year."

The real catalyst was the outlook. After two brutal guidance cuts over the past year left CSL near multi-year lows, management guided to ~5% underlying profit growth in FY27 — a signal the bleeding is over and growth is coming back. RBC's Craig Wong-Pan said CSL "delivered a good FY26 result with beats across revenue, EBITDA and NPATA." A battered, oversold blue-chip finally handing investors a floor is exactly the setup for a violent relief rally.

The ripple: CSL is one of the biggest healthcare weights in the S&P/ASX 200, so a 16% pop in it single-handedly lifted the ASX 200 Health Care index and nudged the whole benchmark higher — every index fund and super fund tracking the ASX 200 got dragged along. It also sets a friendlier tone for global plasma and vaccine peers heading into their own updates.

The risk that flips it: this is a rally on guidance, not delivered numbers. CSL has burned investors twice already by cutting guidance months after issuing it, largely because falling US vaccination rates gutted its Seqirus vaccines arm. The concrete test is the first-half FY27 update: if that ~5% growth path holds, today's move sticks; if vaccination-rate weakness creeps back in, the relief can unwind fast. Watch whether the stock holds above its A$134.60 pre-result base.

As of Tue 18 Aug 2026, midday Sydney trade. Sources: Proactive Investors, Investing.com. For discussion and education only — not investment advice. Verify before acting.